CN110075119A - 一种复方滑石粉止血膏及其制备方法 - Google Patents

一种复方滑石粉止血膏及其制备方法 Download PDF

Info

Publication number
CN110075119A
CN110075119A CN201910389630.5A CN201910389630A CN110075119A CN 110075119 A CN110075119 A CN 110075119A CN 201910389630 A CN201910389630 A CN 201910389630A CN 110075119 A CN110075119 A CN 110075119A
Authority
CN
China
Prior art keywords
talcum powder
hemostatic plaster
compound
tranexamic acid
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910389630.5A
Other languages
English (en)
Inventor
赵滨
何立民
叶赟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201910389630.5A priority Critical patent/CN110075119A/zh
Publication of CN110075119A publication Critical patent/CN110075119A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12Magnesium silicate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21Acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明提供一种复方滑石粉止血膏及其制备方法,成分包括氨甲环酸和滑石粉,且二者的重量比为1:11‑18,滑石粉为纯净的医用滑石粉,不含石棉,加入少量生理盐水搅拌调匀成白色稀糊状即可。以解决目前截骨手术中采用止血带容易出现缺血‑再灌注损伤,术后疼痛肿胀加重,隐性失血较多,且还可能会导致深静脉血栓等并发症的发生等问题。属于截骨创面止血领域。

Description

一种复方滑石粉止血膏及其制备方法
技术领域
本发明涉及一种复方滑石粉止血膏及其制备方法,属于截骨创面止血领域。
背景技术
全膝关节置换术在治疗多种原因引起的终末期膝关节病变疗效得到广泛认可,通过切除坏损骨组织安装人工关节假体,有效的恢复了下肢力线及关节稳定性从而达到恢复患肢功能的目的。TKA术中涉及到股骨远端、胫骨近端的多面截骨,不可避免的导致血液的流失。以往大多数学者采用术中止血带,保证手术视野清晰和骨水泥固定效果等,但是术后松止血带后,会出现再灌注损伤等,不能减少总出血量,还可能会导致一些并发症。自氨甲环酸广泛使用以来,TKA手术患者的总出血量得到明显减少,许多学者术中不再使用止血带或者仅在安装假体时使用。但是在截骨创面上仍存在浸满血液的状况,仍然还存在一定程度的失血,尽量减少术中创面出血,是广大骨科医生努力的方向。
发明内容
本发明的目的在于:提供一种复方滑石粉止血膏及其制备方法,以解决目前截骨手术中采用止血带容易出现缺血-再灌注损伤,术后疼痛肿胀加重,隐性失血较多,且还可能会导致深静脉血栓等并发症的发生等问题。
为解决上述问题,拟采用这样一种复方滑石粉止血膏,包括包括氨甲环酸和滑石粉,且二者的重量比为1:11~18。
前述止血膏中,对于免疫力低,身体条件较差、感染发生可能较大的患者,在配方中另加入头孢唑林钠,氨甲环酸、头孢唑林钠和滑石粉的重量比依次为1:1:11-18;
前述止血膏中,所述滑石粉为纯净的医用滑石粉,无菌无石棉等杂质;
所述复方滑石粉止血膏的制备方法如下:按比例取各组分,加入生理盐水搅拌调匀成白色稀糊状即可。
与现有技术相比,本发明有益效果如下:
1.本发明所述止血膏成本低廉,造价低,每次用药成本最多才几元钱;
2.在不使用止血带的情况下仍然能够极好的实现止血目的,与使用止血带所达到的止血效果基本一致,却不会造成缺血-再灌注损伤,并且避免了使用止血带所带来的并发症;
3.相比现有喷洒于骨创面的止血方法相比,在成本极大降低的基础上,本发明所述止血膏由于主要成分是滑石粉,具有抗粘、抗酸、润滑、吸附力强、化学性质极不活泼等良好的特性,具有一定的抑菌效果,颗粒小,总面积大,可吸附大量细小化学物质和毒性物质,当作用于破损组织上时可起到一定的保护作用;当涂覆于截骨面时可很大程度的填塞截骨面缝隙,从物理上起到止血作用,也增强了氨甲环酸的止血效果;同时滑石粉很不稳定,易移动,在安装假体前脉冲冲洗很容易将其清除干净,留下清洁、清晰的骨小梁创面,基本等同于止血带下的骨创面;
4.本发明所用头孢类抗生素抗菌谱广,半衰期较长,维持有效血药浓度较为持久,术中将配有抗生素的止血膏直接涂覆于截骨面在一定程度上起到降低感染发生率的作用;
5.本发明在术中使用止血膏涂覆于截骨面,有效减少了术中的失血量,而未增加不良反应的发生。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合实施例对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例,基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
本实施例提供一种复方滑石粉止血膏,包括氨甲环酸0.5g、头孢唑林钠0.5g和滑石粉7.5g,滑石粉为纯净的医用滑石粉,不含石棉,加入少量生理盐水搅拌调匀成白色稀糊状备用即可。
实施例2:
本实施例提供一种复方滑石粉止血膏,包括氨甲环酸0.7g、头孢唑林钠0.7g和滑石粉8g,滑石粉为纯净的医用滑石粉,不含石棉,加入少量生理盐水搅拌调匀成白色稀糊状备用即可。
实施例3:
本实施例提供一种复方滑石粉止血膏,包括氨甲环酸1g、头孢唑林钠1g和滑石粉9g,滑石粉为纯净的医用滑石粉,不含石棉,加入少量生理盐水搅拌调匀成白色稀糊状备用即可。
临床实例:
基本资料收取2017年2月-2017年8月因骨性关节炎晚期在贵阳市第四人民医院行单侧人工全膝关节置换术的患者,患者共32例,年龄61-85岁,其中男14例,女18例,平均随访时间6个月(4-9个月)。
本次研究所纳入的患者的手术均由同一手术团队完成,麻醉方式一致,术中均不使用止血带。
止血膏使用时机与方式:在行TKA术中,截骨顺序为:股骨远端-胫骨平台-4面截骨-髁间窝,截骨后将稀糊状止血膏涂覆于截骨面,轻轻挤压,使配制的止血膏进入骨小梁孔隙中,起到止血作用。安装假体前用脉冲水枪将截骨面止血膏清除干净,干纱布挤压、擦拭、吸附创面,此时创面干净、清晰,无需再用止血带。常规安装股骨、胫骨假体及垫片。术后不放置引流管,止血膏配方为:氨甲环酸0.5g、头孢唑林钠0.5g和滑石粉8g。
观察记录记录术中失血量、术后一周内伤口情况、术后一周患肢功能情况(优、良、可、差)。其中术一周计算总失血量,术后一周内伤口情况主要包括切口渗出、红肿、张力性水泡等。术后一周患肢功能情况根据HSS评分量表评估。
表一 术后1、3、5、7天伤口情况
术后一周患肢功能情况及术后3-9个月随访情况
结果:TKA术中经止血膏涂覆截骨面明显减少了术中失血量,术中失血量平均为140ml(经称重换算贵阳市第四人民医院每块完全沾血湿透的纱布约含35mL血液),较以往相似病例(无止血带条件下无止血膏涂覆术中失血量约300-400mL)相比术中失血量明显减少。术后一周内所有患者均未出现明显不良反应。术后一周患肢功能:优11例、良17例、可4例,优良率87.5%。术后平均随访6个月(3-9个月)无血栓症状发生者,无一例因本次手术致死者,无术后感染、假体松动、疼痛剧烈而再次入院治疗者,2例因术后3个月术肢屈伸功能不满意入院行膝关节手法松解术。
讨论:
人工全膝关节置换术在治疗老年退变性膝骨关节炎方面取得了很好的疗效,但是术中、术后失血仍然是骨科医生及其关注的问题,尽可能的减少TKA围手术期失血量依然极为重要。以往止血带的使用有效减少了术中的失血量,提供了一个干洁的手术野,但是止血带可能带来一些不良反应。多数学者提倡缩减止血带的使用时间,认为可有效减轻术后早期患者的疼痛肿胀,而并不增加总失血量。以往采用短程止血带进行膝关节置换,即安装正式假体时使用,以保证在干燥的截骨面进行骨水泥固定。
受到医用胶水在血管外科辅助止血的启发,曾尝试使用医用胶水喷洒截骨创面进行止血,也能取得减少术中出血的效果,但是其价格比较昂贵,容易粘附在骨与软组织上,不易彻底清除。
该止血膏配方中有氨甲环酸、头孢类抗生素、滑石粉。氨甲环酸:一种具有靶向性和高效性的抗纤溶药物,通过抑制纤溶酶原的活化起到止血的作用,它物优价廉,在临床上得到广泛认可,应用十分普遍。最常见的应用方式为静脉滴注和关节腔内局部注射给药。国内外相关报道证实了这两种方式都可有效减少TKA术后失血量。本发明在术前静滴氨甲环酸的基础上,术中再用止血膏涂覆截骨面,有效增强了氨甲环酸在截骨面处的止血效果。
止血膏所含成分中:头孢唑林钠:其抗菌谱广,半衰期较长,有效血药浓度较为持久。术中将配有抗生素的止血膏直接涂覆于截骨面可起到降低感染发生率的作用。配制止血膏所用的医用滑石粉:其主要成分是含水的硅酸镁,具有抗粘、抗酸、润滑、吸附力强、化学性质极不活泼等良好的特性。Zazenski R等经研究表明滑石粉还具有一定的抑菌效果;滑石粉颗粒小,总面积大,可吸附大量细小化学物质和毒性物质,当作用与破损组织上时可起到一定的保护作用。当涂覆于截骨面时可很大程度的填塞截骨面缝隙,从物理作业上起到止血作用,也增强了氨甲环酸的止血效果。同时滑石粉很不稳定,易移动,在安装假体前脉冲冲洗很容易将其清除干净,留下清洁、清晰的骨小梁创面,基本等同于止血带下的骨创面。
滑石粉的灭菌有专门的要求,为了防止其因灭菌不合格导致手术感染,在使用于人体内前进行了十余次的细菌培养,均为阴性结果,在TKA使用中,也多次进行细菌培养,均无细菌生长;所用接受止血膏处理创面的患者也无一例感染。为了明确骨创面在冲洗后无滑石粉残留,在安装人工关节假体前多次取小块骨创面组织,显微镜下证实无残留。
Martin等经随机分组对照研究后发现关节腔内局部应用氨甲环酸并没加大血栓的发生率。也有相关研究比较了静脉和局部应用氨甲环酸对血栓形成的影响,结果显示两种应用方式在血栓形成方面无明显差异。本发明在术前静滴氨甲环酸及术毕关节腔局部注射氨甲环酸的基础上增加术中止血膏涂覆于截骨面,有效减少了术中的失血量,而未增加不良反应的发生。
以上实施例仅用以说明而非限制本发明的技术方案,尽管参照上述实施例对本发明进行了详细说明,本领域的普通技术人员应该理解:依然可以对本发明进行修改或者等同替换,而不脱离本发明的精神和范围的任何修改或局部替换,其均应涵盖在本发明的权利要求范围当中。

Claims (5)

1.一种复方滑石粉止血膏,其特征在于:包括氨甲环酸和滑石粉,且二者的重量比为1:11~18。
2.根据权利要求1所述一种复方滑石粉止血膏,其特征在于:还包括有头孢唑林钠。
3.根据权利要求2所述一种复方滑石粉止血膏,其特征在于:氨甲环酸、头孢唑林钠和滑石粉的重量比依次为1:1:11-18。
4.根据权利要求1所述一种复方滑石粉止血膏,其特征在于:所述滑石粉为纯净的医用滑石粉。
5.权利要求1至4所述复方滑石粉止血膏的制备方法,其特征在于,具体方法如下:按比例取各组分,加入生理盐水搅拌调匀成白色稀糊状即可。
CN201910389630.5A 2019-05-10 2019-05-10 一种复方滑石粉止血膏及其制备方法 Pending CN110075119A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910389630.5A CN110075119A (zh) 2019-05-10 2019-05-10 一种复方滑石粉止血膏及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910389630.5A CN110075119A (zh) 2019-05-10 2019-05-10 一种复方滑石粉止血膏及其制备方法

Publications (1)

Publication Number Publication Date
CN110075119A true CN110075119A (zh) 2019-08-02

Family

ID=67419718

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910389630.5A Pending CN110075119A (zh) 2019-05-10 2019-05-10 一种复方滑石粉止血膏及其制备方法

Country Status (1)

Country Link
CN (1) CN110075119A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1709507A (zh) * 2005-06-29 2005-12-21 肖春 外用复方止血镇痛消炎药
CN104490762A (zh) * 2014-12-26 2015-04-08 陈长潭 一种氨甲环酸外用半固体制剂及制备方法
CN106265581A (zh) * 2016-09-30 2017-01-04 上海信谊万象药业股份有限公司 一种氨甲环酸片及其制备方法
US20180116986A1 (en) * 2016-10-28 2018-05-03 Hemant N. Joshi Composition of novel powder formulations of tranexamic acid
CN109453418A (zh) * 2018-11-16 2019-03-12 南阳市中心医院 一种血管外科用止血抗菌敷料

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1709507A (zh) * 2005-06-29 2005-12-21 肖春 外用复方止血镇痛消炎药
CN104490762A (zh) * 2014-12-26 2015-04-08 陈长潭 一种氨甲环酸外用半固体制剂及制备方法
CN106265581A (zh) * 2016-09-30 2017-01-04 上海信谊万象药业股份有限公司 一种氨甲环酸片及其制备方法
US20180116986A1 (en) * 2016-10-28 2018-05-03 Hemant N. Joshi Composition of novel powder formulations of tranexamic acid
CN109453418A (zh) * 2018-11-16 2019-03-12 南阳市中心医院 一种血管外科用止血抗菌敷料

Similar Documents

Publication Publication Date Title
US4414202A (en) Composition for treatment of wounds
US4778679A (en) Method and composition for treatment of wounds
CN108135965B (zh) 用于伤口愈合的含p物质的药物组合物
CN104083398A (zh) 一种医用防护冲洗液及其制备方法
WO2008026310A1 (fr) Agent protecteur pour une muqueuse orale contenant du tréhalose
Abdelaziz et al. Chemomechanical caries removal agents and their applications in pediatric dentistry
JP6595717B2 (ja) 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法
WO2016080158A1 (ja) 創傷治癒を促進し生体諸臓器の被覆(コーチング)及び庇護を目的とした生体皮膜剤
CN110075119A (zh) 一种复方滑石粉止血膏及其制备方法
EP0034504B1 (en) Combinations for the treatment of wounds
WO2009027823A2 (en) Pharmaceutical composition for selective stimulation of wound healing processes, dermal-epidermal normal tissular trophism processes, its preparation and application.
Morison The treatment of infected suppurating war wounds
CN104490760A (zh) 辣椒碱-胶原蛋白海绵的制备方法及其应用
WO2014181299A1 (en) A product for use in the therapeutic treatment of periodontitis and peri- implantitis
MacGregor Treatment of soft warts with podophyllin
RU2220729C2 (ru) Гелевая композиция, используемая в стоматологии
RU2795082C1 (ru) Способ получения кальцийфосфатного матрикса на основе самосхватывающейся композиции с антибактериальными свойствами для коррекции патологии опорно-двигательной системы пациента
Holder et al. The application of carbamide (urea) therapy in wound healing
RU2003346C1 (ru) Композици дл ферментативного гидролиза белков
CN106794187A (zh) 用于骨、软骨、牙齿和牙周组织再生和治疗肿瘤与囊肿的制剂
CN102580104A (zh) 一种用于腔道检查或治疗的麻醉药物组合物及制备方法
RU2288701C2 (ru) Состав для лечения альвеолита
SU1421312A1 (ru) Способ лечени гнойных ран
RU2455008C1 (ru) Пролонгированная жидкая лекарственная форма на основе бишофита
CN116725949A (zh) 盐酸布比卡因及多聚脱氧核糖核苷酸缓释凝胶注射液及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190802

RJ01 Rejection of invention patent application after publication